 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Bethlehem facility from 18th September 2023 to 27th September 2023.

Piramal Pharma up almost 4% on green signal from US FDA for Bethlehem plant

Varun Beverages traded well above all key moving averages (20, 50, 100 and 200-day EMA - exponential moving average) and saw a breakout of falling resistance trendline adjoining highs of September 29, and November 6, which is a positive sign.

Trade Spotlight | Your strategy for Piramal Pharma, Varun Beverages, Cochin Shipyard today

Motilal Oswal is bullish on Piramal Pharma recommended buy rating on the stock with a target price of Rs 115 in its research report dated October 30, 2023.

Buy Piramal Pharma; target of Rs 115: Motilal Oswal

FACT formed strong bullish candlestick pattern on the daily timeframe, with above average volumes. Also, the stock traded well above all key moving averages, which is a positive sign.

Trade Spotlight | How you should deal in Piramal Pharma, CDSL and FACT counters

Piramal Pharma Consolidated September 2023 Net Sales at Rs 1,911.38 crore, up 11.13% Y-o-Y

Overall, the index has still been in the range with 19,750-19,800 likely to act as a crucial resistance as breaking of the same can drive the Nifty50 towards 20,000 mark, whereas 19,500 is expected to be immediate support and 19,200 may be crucial support for the index, experts said

Ten best bets for Oct series as bulls may charge when Nifty holds 19,800

CMS Info Systems shares fell more than 7 percent to Rs 363 on the NSE.

Bulk deals | Promoter Sion Investment Holdings sells 19.43% stake in CMS Info Systems

CA Alchemy had held 20 percent stake or 23.86 crore equity shares in Piramal Pharma as of June 2023.

Bulk Deals: PHI Capital Trust exits Minda Corporation, Carlyle Group offloads 2.17% stake in Piramal Pharma

Motilal Oswal is bullish on Piramal Pharma recommended buy rating on the stock with a target price of Rs 125 in its research report dated August 04, 2023.

Buy Piramal Pharma; target of Rs 125: Motilal Oswal

EBITDA margin for the June quarter grew to 10 percent up from 6 percent in Q1FY23.

Piramal Pharma trades lower by over 2% after Q1 earnings

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. It offers skin care, vitamins and nutrition, antacids, analgesics, gastro-intestinal, and baby-care. The company was founded on March 4, 20202 and is headquartered in Mumbai, India.

Watchers	146
52-Wk Low	63.10
52-Wk High	143.40

Volume (M)	5.23M
52-Wk High	143.40
52-Wk Low	63.10

PPLPHARMA.NSE Piramal Pharma Limited

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community